Clinical trial successes often lead to increased investor confidence as they pave the way for potential product approvals and market expansions. The positive outcome of the LINKER-MM1 trial suggests that Regeneron's Linvoseltamab could become a significant treatment option for multiple myeloma, which may result in increased revenues and a positive impact on the stock price in the short term.